Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation

Area of Science:

• Neuroscience
• Biochemistry
• Endocrinology

Background:

• Alzheimer's disease (AD) is linked to amyloid-beta (Aβ) plaques.
• Epidemiological studies suggest a correlation between low vitamin D levels and AD.
• The precise mechanisms of vitamin D's influence on Aβ homeostasis and the effects of its analogues are not fully understood.

Purpose of the Study:

• To investigate the effects of vitamin D and its therapeutic analogues on AD-relevant mechanisms.
• To explore the impact of vitamin D on amyloid-beta (Aβ) production and degradation pathways.
• To elucidate the role of vitamin D in modulating key enzymes involved in Aβ metabolism.

Main Methods:

• Systematic investigation of vitamin D and analogues (maxacalcitol, calcipotriol, alfacalcidol, paricalcitol, doxercalciferol).
• Assay of Aβ production and degradation in neuroblastoma cells and mouse brains.
• Analysis of BACE1 and γ-secretase activity, BACE1 protein levels, and nicastrin expression.

Main Results:

• Vitamin D and its analogues reduced Aβ production and increased Aβ degradation.
• These effects were mediated by influencing BACE1 and γ-secretase activity.
• Reduced secretase activity correlated with decreased BACE1 protein and nicastrin levels, even in non-deficient mice.

Conclusions:

• Vitamin D and its analogues demonstrate a potential to modulate key pathways in Alzheimer's disease.
• Supplementation with vitamin D or its analogues may offer a preventative strategy for AD.
• Further research into vitamin D's therapeutic potential for AD is warranted.